LGALS3BP抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P08478(LGALS3BP Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P08478(LGALS3BP Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

LGALS3BP (Galectin-3 Binding Protein), also known as 90K or Mac-2BP, is a secreted glycoprotein involved in immune regulation, cell adhesion, and signal transduction. It was initially identified as a tumor-associated antigen due to its elevated expression in various cancers. Structurally, it contains multiple functional domains, including scavenger receptor cysteine-rich (SRCR) domains, enabling interactions with galectin family proteins (e.g., Galectin-3) and integrins. These interactions modulate processes like cell-matrix adhesion, apoptosis, and immune responses. LGALS3BP is found in extracellular matrices and body fluids (e.g., blood, saliva) and is implicated in viral infections (HIV, HCV), autoimmune disorders, and cancer progression, where its overexpression often correlates with poor prognosis.

Antibodies targeting LGALS3BP are critical tools for studying its biological roles and clinical applications. They are used in immunoassays (ELISA, Western blot, immunohistochemistry) to quantify LGALS3BP levels in tissues or fluids, aiding cancer diagnosis and monitoring. In research, these antibodies help elucidate LGALS3BP's role in tumor microenvironments, immune evasion, and metastasis. Therapeutic potential is also explored, as blocking LGALS3BP-galectin interactions may inhibit cancer progression or enhance antiviral immunity. However, its dual roles—acting as both a tumor suppressor and promoter in different contexts—highlight the complexity of targeting LGALS3BP. Validated antibodies with high specificity are essential to ensure reliable experimental and diagnostic outcomes.